BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 30001824)

  • 21. A Multicenter Study of the Clinical Utility of Nontargeted Systematic Transperineal Prostate Biopsies in Patients Undergoing Pre-Biopsy Multiparametric Magnetic Resonance Imaging.
    Connor MJ; Eldred-Evans D; van Son M; Hosking-Jervis F; Bertoncelli Tanaka M; Reddy D; Bass EJ; Powell L; Ahmad S; Pegers E; Joshi S; Sri D; Wong K; Tam H; Hrouda D; Qazi H; Gordon S; Winkler M; Ahmed HU
    J Urol; 2020 Dec; 204(6):1195-1201. PubMed ID: 32516029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
    Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
    Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
    Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
    JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility.
    van der Leest M; Israël B; Cornel EB; Zámecnik P; Schoots IG; van der Lelij H; Padhani AR; Rovers M; van Oort I; Sedelaar M; Hulsbergen-van de Kaa C; Hannink G; Veltman J; Barentsz J
    Eur Urol; 2019 Nov; 76(5):574-581. PubMed ID: 31167748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study.
    Waldén M; Aldrimer M; Lagerlöf JH; Eklund M; Grönberg H; Nordström T; Palsdottir T
    Eur Urol Open Sci; 2022 Apr; 38():32-39. PubMed ID: 35495282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
    Palsdottir T; Grönberg H; Hilmisson A; Eklund M; Nordström T; Vigneswaran HT
    Eur Urol Focus; 2023 May; 9(3):455-462. PubMed ID: 36522257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial.
    Light A; Kanthabalan A; Otieno M; Pavlou M; Omar R; Adeleke S; Giganti F; Brew-Graves C; Williams NR; Emara A; Haroon A; Latifoltojar A; Sidhu H; Freeman A; Orczyk C; Nikapota A; Dudderidge T; Hindley RG; Virdi J; Arya M; Payne H; Mitra AV; Bomanji J; Winkler M; Horan G; Moore CM; Emberton M; Punwani S; Ahmed HU; Shah TT
    Eur Urol; 2024 Jan; 85(1):35-46. PubMed ID: 37778954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy.
    Patel N; Cricco-Lizza E; Kasabwala K; Xu C; Robinson BD; Khani F; Wang Y; Margolis D; Hu JC
    Eur Urol Oncol; 2018 Sep; 1(4):263-267. PubMed ID: 31100246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.
    Lai WS; Gordetsky JB; Thomas JV; Nix JW; Rais-Bahrami S
    Cancer; 2017 Jun; 123(11):1941-1948. PubMed ID: 28140460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening.
    Andersson J; Palsdottir T; Lantz A; Aly M; Grönberg H; Egevad L; Eklund M; Nordström T
    Eur Urol Open Sci; 2022 Oct; 44():69-75. PubMed ID: 36185581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Winther MD; Jakobsen H; Thomsen HS
    JAMA Netw Open; 2018 Jun; 1(2):e180219. PubMed ID: 30646066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.
    Sonn GA; Chang E; Natarajan S; Margolis DJ; Macairan M; Lieu P; Huang J; Dorey FJ; Reiter RE; Marks LS
    Eur Urol; 2014 Apr; 65(4):809-15. PubMed ID: 23523537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.
    Filson CP; Natarajan S; Margolis DJ; Huang J; Lieu P; Dorey FJ; Reiter RE; Marks LS
    Cancer; 2016 Mar; 122(6):884-92. PubMed ID: 26749141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
    Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
    Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
    Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study.
    Elkhoury FF; Felker ER; Kwan L; Sisk AE; Delfin M; Natarajan S; Marks LS
    JAMA Surg; 2019 Sep; 154(9):811-818. PubMed ID: 31188412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study.
    Eldred-Evans D; Tam H; Sokhi H; Padhani AR; Connor M; Price D; Gammon M; Klimowska-Nassar N; Burak P; Day E; Winkler M; Fiorentino F; Ahmed HU
    Eur Urol Oncol; 2023 Jun; 6(3):295-302. PubMed ID: 37080821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Thomsen HS
    Urol Int; 2017; 99(4):384-391. PubMed ID: 28651247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of information on prostate biopsy history on biopsy outcomes in the era of MRI-targeted biopsies.
    Lantz A; Haug ES; Picker W; Crippa A; Jäderling F; Mortezavi A; Nordström T
    World J Urol; 2021 Apr; 39(4):1153-1159. PubMed ID: 32472278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
    Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
    Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.